Evidence map›Paper›PMID 31942044›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2020

Pretreatment with cilnidipine attenuates hypoxia/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening.

Hiroyuki Minato, Ichiro Hisatome, Yasutaka Kurata, Tomomi Notsu, Naoe Nakasone, Haruaki Ninomiya, Toshihiro Hamada, Takuya Tomomori, Akihiro Okamura, Junichiro Miake and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Does cilnidipine, a dual L- and N-type CaHypertension research : official journal of the Japanese Society of Hypertension · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Hiroyuki MinatoDepartment of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan.
Ichiro HisatomeDepartment of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan.
Yasutaka KurataDepartment of Physiology II, Kanazawa Medical University, Ishikawa, 920-0268, Japan. yasu@kanazawa-med.ac.jp.
Tomomi NotsuDepartment of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan.
Naoe NakasoneDepartment of Biological Regulation, Tottori University, Yonago, 683-8503, Japan.
Haruaki NinomiyaDepartment of Biological Regulation, Tottori University, Yonago, 683-8503, Japan.
Toshihiro HamadaDepartment of Community-Based Family Medicine, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan.
Takuya TomomoriDepartment of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan.
Akihiro OkamuraDepartment of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan.
Junichiro MiakeDepartment of Pharmacology, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan.
Motokazu TsunetoDepartment of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan.
Yasuaki ShirayoshiDepartment of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan.
Ryo EndoDepartment of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan.
Akihiro OtsukiDepartment of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan.
Futoshi OkadaDivision of Pathological Biochemistry, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan.
Yoshimi InagakiDepartment of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan.
Tottori University · JPKanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia/reperfusion injury worsens in the absence of nitric oxide synthase (NOS). Cilnidipine, a Ca

Indexed as

Action PotentialsAnimalsApoptosisCalcium Channel BlockersCell LineCell SurvivalDihydropyridinesGene Knockdown TechniquesHypoxiaMiceMyocytes, CardiacNitric OxideNitric Oxide Synthase Type IIIPhosphorylationRatsRNA, Small InterferingCalcium Channel BlockerscilnidipineDihydropyridinesNitric OxideNitric Oxide Synthase Type IIIRNA, Small InterferingAction potentialCilnidipineeNOSIschemia reperfusionNO

Identifiers

PMID31942044
OpenAlexW3000328714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.